Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial

By afschroeder • October 2, 2025

Kishan AU, Juarez Casillas JE, Sargos P, Kalbasi TR, Chabaud S, Brihoum M, Sachdeva A, Nikitas JN, Ma TM, Karasik D, Ballas LK, Lock D, Valle L, Taparra K, Reiter RE, Saigal C, Chamie K, Donin N, Chin AI, Rettig M, Nickols NG, Sun Y, Spratt D, Lamb JM, Cao M, Pommier P, Steinberg ML. Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial. Eur Urol. 2025 Sep 30:S0302-2838(25)04699-8. doi: 10.1016/j.eururo.2025.09.4149. Epub ahead of print. PMID: 41033921.

Tags: Biochemical recurrence–free survival, DOM STAT, Gastrointestinal toxicity, General Internal Medicine, Genitourinary toxicity, Hematology/Oncology, Magnetic resonance imaging guidance, patient-reported outcomes, Postoperative radiotherapy, prostate cancer, Prostatic fossa, Publications, Quality of Life, Stereotactic body radiotherapy, Veterans Administration

Zero-shot medical event prediction using a generative pretrained transformer on electronic health records

Redekop E, Wang Z, Kulkarni R, Pleasure M, Chin A, Hassanzadeh HR, Hill BL, Emami M, Speier WF, Arnold CW. Zero-shot medical event prediction using[...]

Federal Housing Assistance and Stage at Cancer Diagnosis Among Older Adults in the US

Pollack CE, Blackford AL, Craig TK, Fan Q, Hussaini SMQ, Chen KL, Polsky D, Katana Ogongo M, Warren JL, Gross CP, Yabroff KR. Federal Housing[...]

Bridging gaps throughout a patient’s journey with melanoma: a systematic review

Amarsi A, Xu J, Chan J, Jiang YC, Omar AZ, Meghdadi Y, Doshi A, Xie A, Wu A. Bridging gaps throughout a patient's journey with[...]